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NC-ND license (http://creativecommoBackground: Troponin I, myoglobin, and creatine kinase-MB mass (CK-MB) are biomarkers of
cardiomyocyte injury widely used in the management of adult patients. The role of these bio-
markers in newborns is still not established. The purpose of this study was to evaluate the
value of cardiac injury biomarkers in newborns with congenital heart disease.
Methods: From August 2012 to January 2014, 34 newborns with a prenatal diagnosis of congen-
ital heart disease were admitted consecutively to a neonatal intensive care unit. As controls,
20 healthy newborns were recruited. Plasma levels of cardiac biomarkers (troponin I,
myoglobin, and CK-MB) were evaluated, and echocardiography was performed to evaluate car-
diac function on D 1. Patients were followed during the first 28 days of life and, according to
outcome, categorized as surgical or conservative treatment group.
Results: Median (P25e75) levels of CK-MB were higher in patients who underwent cardiac sur-
gery in the neonatal period [7.35 (4.90e13.40) ng/mL] than in patients who were discharged
home without surgery [4.2 (2.60e5.90) ng/mL; p Z 0.032]. A CK-MB cutoff of  4.6 ng/mLof Paediatric Cardiology, Hospital Sa˜o Joa˜o, Alameda Professor Hernaˆni Monteiro, 4200e319 Porto,
m (A.L. Neves).
015.11.004
ediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
ns.org/licenses/by-nc-nd/4.0/).
Biomarkers in congenital heart disease 489showed sensitivity of 87.5% and specificity of 63.6%. Troponin I and myoglobin levels were not
significantly different between conservative and surgical treatment groups. CK-MB levels
correlated with the tissue Doppler image of the mitral valve lateral annulus peak early/late
diastolic velocity ratio (r Z 0.480, p Z 0.018).
Conclusion: CK-MB levels during the first hours of life were higher in newborns that needed
neonatal cardiac surgery, and these levels may be an indicator of myocardial diastolic func-
tion.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Creatine kinase-MB mass (CK-MB), myoglobin, and cardiac
troponins I and T are cardiac injury biomarkers widely used
in the management of adult patients.1,2 Interest in these
cardiac biomarkers in the management of children with
congenital heart disease (CHD) has increased; however,
there are no current guidelines for their routine use.
Reference values for CK-MB and cardiac troponins T and I in
healthy neonates have been published.3e6 CK-MB levels
were elevated in newborns after perinatal and neonatal
hypoxiaeischemia, but this elevation was not specific
enough to be of clinical value.7 Myoglobin is a cytoplasmic
protein in cardiac and skeletal muscle, and it passes rapidly
into circulation after damage to the myocytes.6,8 Troponin I
was found to be a very sensitive and specific marker of
cardiac injury.2,4,9 Troponin I has been used to detect
myocardial compromise in newborns with hypoxia and
asphyxia,10,11 and it was shown to be useful for monitoring
myocardial injury in infants of diabetic mothers: an
elevated troponin I in infants of diabetic mothers with
respiratory distress was a good predictor of hypertrophic
cardiomyopathy and/or left ventricular dysfunction.12
Troponin I has also been studied in children with left-to-
right shunt-induced myocardial injury.13,14 Further
research is necessary before cardiac injury biomarkers can
be used in clinical practice in this age group.15,16
Our hypothesis was that plasma cardiac injury bio-
markers might be increased in newborns with CHD, corre-
lated with echocardiographic markers of biventricular
function, and useful in the management of these patients.
2. Methods
2.1. Study design and patient population
This is a prospective study of 34 consecutive newborns with
a prenatal diagnosis of CHD, who were admitted at the
Neonatal Intensive Care Unit of S. Joa˜o Hospital Center,
Porto, Portugal, between August 2012 and January 2014.
Additionally, 20 healthy newborns delivered in the same
hospital were recruited as controls. Plasma biomarkers
were evaluated on Day 1 (with umbilical cord blood after
birth or the first sample collected for clinical purposes).
The umbilical cord blood was collected after birth following
the standard protocol. In the few cases in which it was notpossible to collect a cord sample (spasm of the cord or
sample coagulation), the peripheral venous blood was
collected as soon as a clinical sample for the newborn was
performed (the first few hours of life).
Plasma biomarkers evaluated were troponin I,
myoglobin, and CK-MB. In all control group newborns
except for one, all the biomarkers were measured. In the
CHD group, troponin I was available in 33, myoglobin in 26,
and CK-MB in 26. The missing values were due to insuffi-
cient sample volume.
Plasma biomarkers were compared using all patients’
samples and also using only cord blood samples. Troponin I,
myoglobin, and CK-MB were measured by way of chemilu-
minescent immunoassays using an Architect i2000 auto-
mated analyzer (Abbott, Lisboa, Portugal).
CHD cases were subdivided into right ventricle pressure
overload (n Z 6), left ventricle pressure overload (n Z 5),
Ebstein disease (n Z 2), transposition of great arteries
(n Z 4), left-to-right shunts (n Z 6), and total pulmonary
anomalous venous return (n Z 1) groups.
The right ventricle pressure overload group included
four patients with tetralogy of Fallot, one patient with
double outlet right ventricle with pulmonary stenosis, and
one patient with pulmonary atresia with ventricular septal
defect. The left ventricle pressure overload group included
two patients with coarctation of the aorta, one patient with
aortic stenosis, one patient with aortic atresia with ven-
tricular septal defect, and one patient with interruption of
the aortic arch. The group of transposition of great arteries
included two patients with transposition of great arteries
and two patients with transposition of great arteries with
ventricular septal defects. The left-to-right shunt group
included three patients with atrioventricular septal de-
fects, two patients with ventricular septal defects, and one
patient with patent ductus arteriosus (PDA). Two patients
were excluded because they did not have a surgical indi-
cation (supraventricular tachycardia and a small muscular
ventricular septal defect).
Patients were followed during the first 28 days of life
(neonatal period) and, according to the outcome, catego-
rized as surgical or conservative treatment group.
Of the 24 patients with CHD with a surgical indication
(with a type of CHD expected to require surgery at some
point in life), 10 had cardiac surgery in the neonatal period:
systemic to pulmonary shunts (n Z 3), arterial switch
(n Z 2), Norwood (n Z 1), aortic valvuloplasty (n Z 1),
pulmonary banding (n Z 1), correction of coarctation of
490 A.L. Neves et alaorta (nZ 1), and correction of interruption of aortic arch
(n Z 1). The group of transposition of great arteries
included both transposition of great arteries with and that
without ventricular septal defect. The patient with trans-
position of great arteries had two large ventricular septal
defects, and it was not possible to perform the arterial
switch at birth. The total anomalous pulmonary venous
return was corrected after the 1st month of postnatal life;
therefore, it was not included in the neonatal surgical
group (defined as surgery in the first 28 days of life).
2.2. Echocardiographic imaging
Echocardiography was performed on Day 1, using the Gen-
eral Electric Vivid I. Right ventricular, left ventricular
function M-mode, and Doppler and tissue Doppler image
(TDI) parameters were evaluated using standard
techniques.17e20 For left ventricle systolic function, the
evaluated parameters were left ventricle ejection fraction
and mitral valve lateral annulus TDI slope. For right
ventricle systolic function, the parameters were tricuspid
annular plane systolic excursion and tricuspid valve lateral
annulus TDI slope. The mitral TDI E0/A0 was acquired in the
lateral side of the mitral valve annulus. Each of TDI early
diastolic (E0) and late diastolic (A0) myocardial velocities
was measured at the upper lateral annulus of the mitral
valve during periods of stable heart rate and stable TDI
waveforms.21 The apical four-chamber view was used; care
was taken to align the sample volume as vertically as
possible with respect to the cardiac apex,20 and the ratio
E0/A0 was calculated.22 Cardiac performance evaluation was
blinded for blood test results.
2.3. Statistical analysis
Continuous variables were presented as medians (25the75th
percentile) and compared using the ManneWhitney U test.
Proportions were compared through the Chi-square test or
Fisher exact test, as appropriate. Receiver operator char-
acteristic curves were used to evaluate troponin I,
myoglobin, and CK-MB as potential biomarkers. Assays were
deemed to be potentially useful if they carried a c-statistic
of  0.75 (corresponding to  75% of the graph area
encompassed by the curve). For a potentially useful test, a
clinically relevant cutoff was identified that would distin-
guish newborns submitted to surgery from those receiving
conservative treatment.23 Logistic regression models were
fitted to estimate the association between biomarker levels
and cardiac surgery. The association between biomarkers
and echocardiographic parameters was analyzed byTable 1 Biomarker levels in control and congenital heart disea
Med
n Control group
Troponin (ng/mL) 19 0.01 (0.01e0.02)
Myoglobin (ng/mL) 20 50.95 (34.38e73.65)
CK-MB (ng/mL) 19 3.60 (2.70e6.20)
CHD Z congenital heart disease; CK-MB Z creatine kinase-MB mass.Spearman’s rank correlation test. SPSS version 21 (IBM,
Armonk, NY, USA) was used for statistical analysis. A p
value < 0.05 was considered statistically significant.
This study was approved by the Sa˜o Joa˜o Hospital, Porto,
Portugal, Ethics Committee, and parents of all participants
provided written informed consent. The newborns’ physi-
cians were blinded to the results of the biomarkers.
Echocardiography was performed and analyzed blinded for
biomarker results and outcome.
3. Results
The CHD and control groups were similar regarding gesta-
tional age [38 (37e39) weeks in CHD vs. 39 (37e40) weeks in
controls, pZ 0.221], type of delivery (eutocic vs. dystocic,
p Z 0.965), and birth weight [CHD 3092.5 (2891.2e3446.2)
g and control 3157.5 (2771.2e3515.0) g, p Z 0.727].
Cardiac biomarkers were not different between eutocic
and dystocic deliveries (CK-MB, p Z 0.935; troponin,
p Z 0.884; myoglobin, p Z 0.967). Levels of cardiac bio-
markers were not related to patients’ saturation of oxygen
(CK-MB: b Z 0.002, p Z 0.990; troponin: b Z 0.001,
p Z 0.491; myoglobin: b Z 2.79, p Z 0.374) or to Apgar
score at Minute 1 (CK-MB: b Z 0.794, p Z 0.590; troponin:
b Z 0.005, p Z 0.418; myoglobin: b Z 19.20, p Z 0.451)
and Minute 5 (CK-MB: b Z 2.00, p Z 0.300; troponin:
b Z 0.01, p Z 0.428; myoglobin: b Z 32.60, p Z 0.333).
CK-MB and myoglobin were statistically significantly
different according to blood source. For CK-MB, cord blood
median was 4.2 (2.8e6.6) and peripheral venous blood
median 12.1 (5.3e21.6), p Z 0.009; for myoglobin, cord
blood median was 47.20 (33.0e59.0) and peripheral venous
blood median 114.8 (66.5e240.6), p Z 0.002. No differ-
ences were observed regarding troponin [cord blood 0.01
(0.01e0.01), peripheral venous blood 0.01 (0.01e0.04),
p Z 0.189]. Using only the cord blood samples, higher
levels of CK-MB were observed in those who needed
neonatal surgery compared with the newborns that were
discharged home without surgery (7.30 vs. 3.65,
p Z 0.091). In regard to the peripheral blood, the sample
was small (nZ 6), which did not allow us to compare these
groups.
Troponin I, myoglobin, and CK-MB levels were not
significantly different between the control and CHD groups
(Table 1) or between groups of CHD (Table 2).
Surgical and conservative treatment groups were similar
regarding gestational age, type of birth, and birth weight,
and they had a similar Apgar score at 1 minute and 5 mi-
nutes (Table 3). Median (P25e75) levels of CK-MB were
higher in patients who had cardiac surgery in the neonatalse groups.
ian (P25e75) p
n CHD group
33 0.01 (0.01e0.04) 0.710
26 58.30 (33.88e80.55) 0.748
26 4.60 (3.08e7.60) 0.260









RVPO 6 0.01 55.90 4.90
LVPO 5 0.01 55.80 4.20
Ebstein 2 0.02 94.30 8.90
TGA 4 0.01 47.20 7.40
LeR shunt 6 0.01 60.15 2.75
TAPVR 1 0.01 d d
CK-MB Z creatine kinase-MB mass; Ebstein Z Ebstein disease;
LeR shunt Z left-to-right shunts; LVPO Z left ventricle pres-
sure overload; RVPO Z right ventricle pressure overload;
TAPVR Z total pulmonary anomalous venous return;
TGA Z transposition of great arteries.
Table 3 Demographics of patient’s character-













37 (37e40) 38 (38e39) 0.745






1 min 9 (8e9) 9 (8e9) 0.296
5 min 10 (8e9) 9 (9e10) 0.698





LeR shunt 0 6
TAPVR 0 1
Ebstein Z Ebstein disease; LeR shunt Z left-to-right shunts;
LVPOZ left ventricle pressure overload; RVPOZ right ventricle
pressure overload; TAPVRZ total pulmonary anomalous venous
return; TGA Z transposition of great arteries.
Table 4 Cardiac biomarkers by type of treatment (surgical vs.
n Surgical treatment
Median (P25e75)
Troponin (ng/mL) 9 0.01 (0.01e0.03)
Myoglobin (ng/mL) 8 64.90 (49.35e119.93)
CK-MB (ng/mL) 8 7.35 (4.90e13.40)
* p < 0.05.
CK-MB Z creatine kinase-MB mass.
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were discharged home without surgery [4.2 (2.60e5.90) ng/
mL, p Z 0.032]. Troponin I and myoglobin levels were not
significantly different between conservative treatment and
surgical groups (Table 4).
Receiver operator characteristic curves were generated,
which plot a test’s true positives against its false positives,
for CK-MB, troponin I, and myoglobin (Figure 1). CK-MB
exceeded our prespecified threshold of  75% area con-
tained by the receiver operator characteristic curve. The
area under the curve for the plot of CK-MB against surgery
was 79.5%. Test characteristics for various plasma levels of
CK-MB as markers for surgery were determined. A cutoff of
 4.6 ng/mL showed sensitivity of 87.5% and specificity of
63.6%. The proportion of newborns who underwent cardiac
surgery was higher among those who had a CK-MB of 
4.6 ng/mL (p Z 0.026). Those with higher levels of CK-MB
( 4.6 ng/mL) presented an increased likelihood of being
submitted to surgery (odds ratio Z 12.25; confidence in-
terval: 1.08e138.99).
3.1. Correlation between plasma biomarkers and
echocardiographic parameters
There was a statistically significant negative correlation
(Figure 2) between CK-MB levels and TDI of the mitral valve
lateral annulus peak early/late diastolic velocity ratio (MV
E0/A; r Z 0.480, p Z 0.018). Images of measurement of
myocardial diastolic function E0 and A0 waves are exempli-
fied in Figure 3. There was no correlation between CK-MB
and the other echocardiographic parameters that were
evaluated. For the ventricular systolic function parameters
that were evaluated, the median (P25e75) values were
79.0 (69.2e87.0) for left ventricle ejection fraction, 0.046
(0.032e0.050) for mitral valve lateral annulus TDI slope,
7.66 (7.08e9.93) for tricuspid annular plane systolic
excursion, and 0.06 (0.05e0.07) for TDI tricuspid valve
slope. In control participants, there was no statistically
significant correlation between CK-MB and TDI measure-
ments (rZ 0.112, pZ 0.680). Myoglobin and troponin I did
not correlate with echocardiographic parameters.
4. Discussion
Troponin I, myoglobin, and CK-MB were not significantly
higher in newborns with CHD than in healthy newborns,
suggesting that newborns with a prenatal diagnosis of CHD
do not present with ischemia at birth. To date, this is the




0.01 (0.01e0.02) 14 0.505
55.00 (32.00e64.30) 11 0.148
4.2 (2.60e5.90) 11 0.032*
Figure 1 Receiver operator characteristic curves for CK-MB, troponin, and myoglobin. False positives (1-specificty) were plotted
against true positives (sensitivity). A test for which the area under the curve (c-statistic) is  0.75 was defined as a useful test.
AUC Z area under the curve; CK-MB Z creatine kinase-MB mass.
492 A.L. Neves et albiomarkers’ value in newborns with a broad spectrum of
CHD before surgery. Kocylowski et al6 evaluated injury
markers in postpartum cord blood in 10 newborns with CHD.
Troponin T was increased only in two out of 10 newborns
with CHD; in CK-MB and myoglobin there were no differ-
ences from normal. Liesemer et al24 reviewed the use ofFigure 2 Correlation of mitral valve annulus E0/A0 (MV E0/A0) with
CK-MB Z creatine kinase-MB mass; MV E0/A0 Z mitral valve lateratroponin in pediatric practice; however, in the newborn
group (with a variety of diagnosis, including birth asphyxia,
respiratory distress syndrome, meconium aspiration, or
twinetwin transfusion), outcome analysis was not per-
formed. Troponin has been studied in the postoperative
setting with discrepant conclusions. Bottio et al25 evaluatedCK-MB. Spearman correlation coefficientZ 0.480, pZ 0.018.
l annulus peak early/late diastolic velocity ratio.
Figure 3 Tissue Doppler images of (A) myocardial diastolic function (mitral valve lateral annulus E0/A0) from a healthy newborn,
(B) an aortic atresia patient with a ventricular septal defect, (C) transposition of the great arteries, and (D) a tetralogy of Fallot.
Biomarkers in congenital heart disease 493troponin in the postoperative period in newborns and chil-
dren; they concluded that troponin I was a specific and
sensitive marker of myocardial injury after cardiac surgery
and that it might predict early-hospital outcomes, but it
lost prognostic significance over the long term. Bojan et al26
suggested that routine monitoring of troponin I after sur-
gery for CHD was not useful in patients younger than 1 year.
CK-MB was elevated in newborns after perinatal and
neonatal hypoxiaeischemia, but this elevation was not
specific enough to be of clinical value.7,11 Some conditions
such as perinatal hypoxiaeischemia, type of delivery, Apgar
score, and saturation of oxygen may influence cardiac
biomarkers. However, no cases of asphyxia were observed
in our study. Moreover, cardiac biomarkers did not differ
according to the mode of delivery, Apgar score, or patient’s
saturation of oxygen.
To date, the present study is the only one to show a
correlation between cardiac injury biomarkers and TDI in
newborns with CHD. CK-MB was negatively correlated with
MV E0/A0. This TDI parameter may be obtained in all CHD and
allow us to evaluate the diastolic function of these new-
borns. Previously, TDI E0/A0 ratio of three ventricular walls
was evaluated from fetus to neonate and was increased
during the transition from fetal to neonatal circulation.27
TDI E0/A0 was previously used in newborns of diabetic
mothers, and a significant decrease of the E0/A0 ratio at the
tricuspid annulus was found in infants of mothers with pre-
gestational diabetes compared with those with gestational
diabetes.28 Kim et al22 evaluated TDI E0/A0 parameter as a
marker of diastolic function and correlated it with brain
natriuretic peptide (BNP) levels in a population of livertransplant recipients. TDI has also been used in newborns for
each myocardial segment, including peak early diastolic
velocity (E0) and peak late diastolic velocity (A0), to evaluate
postnatal left ventricular diastolic function after fetal aortic
valvuloplasty. Mitral annular early diastolic tissue velocity
(E0) was lower in patients with fetal aortic valvuloplasty and
those with aortic stenosis than in controls in the neonatal
period.21 Dubin et al29 studied the associations between TDI
and NT-proBNP, and concluded that TDI imaging may be
more useful than traditional measures of diastolic function
in a population of end-stage renal disease.
In neonates with respiratory distress syndrome, there
was a statistically significant negative correlation between
cardiac troponin T on Day 1 and the fractional shortening
measured on the same day; however, there was no statis-
tically significant correlation between left ventricular
output and cardiac troponin T across the 3 days.30 No cor-
relations were found between troponin I and echocardio-
graphic measurements in perinatal asphyxia.31 The
diagnostic role of troponin T has been studied in a group of
newborns with CHD, and troponin T levels in newborns with
heart pathology were higher than those in healthy ones.
However, troponin T concentrations in patients with CHD
were correlated neither with clinical symptoms of heart
failure, nor with echocardiographic markers of left ven-
tricular function.32 The absence of a correlation between
cardiac output and cardiac biomarkers may be because of
the presence of a PDA, which would lead to an increased
left ventricular output without increasing systemic blood
flow.30,33 In the presence of a PDA, left ventricular output
does not reflect the systemic blood flow.19
494 A.L. Neves et alThe limitations of the present study are the number of
participants and the lack of biomarker monitoring over time
and postsurgery. CK-MB and myoglobin were different
depending on the blood source. The cord blood levels
(collected immediately after birth) were lower than the
peripheral venous blood levels (collected in the first few
hours after birth). This may be explained by the circulatory
transition from fetal to neonatal life. In healthy newborns,
biomarker concentrations are highest during the first 4 days
of life, possibly due to the stress of the birth process and
due to adaptation of the neonate to postnatal circulation.34
In newborns with CHD, this transition process may have
even more hemodynamic impact since the ductus closure,
the decrease in pulmonary vascular resistance, and the
increase in systemic vascular resistance may overload the
heart, explaining the higher biomarker levels after birth. An
understanding of fetal hemodynamics and the acute and
chronic changes that occur with the transition from fetal to
newborn circulation are important for the care of the
healthy newborns and crucial to the recognition, diagnosis,
and management of the newborn with significant CHD.35,36
In conclusion, CK-MB levels in the first hours of life are
higher in newborns that need neonatal cardiac surgery and
may be an indicator of myocardial diastolic function. TDI
may be more useful than traditional measures of diastolic
function in a population of newborns with CHD. Evaluation
of cardiac biomarkers in umbilical cord blood is feasible and
may be routinely used as part of the management of new-
borns with CHD.
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